Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.820
+0.150 (5.62%)
Dec 24, 2024, 1:00 PM EST - Market closed
Nuvation Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 6.33, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 124.47% from the current stock price of 2.82.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2024.
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +112.77% | Nov 7, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +77.30% | Oct 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +148.23% | Sep 16, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +77.30% | Sep 11, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +77.30% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
2.22M
Revenue Next Year
2.22M
from 2.22M
Decreased by -0.40%
EPS This Year
-2.21
from -0.35
EPS Next Year
-0.64
from -2.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.3M | 3.5M | 107.5M | |||
| Avg | 2.2M | 2.2M | 67.3M | |||
| Low | 2.1M | n/a | 29.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 55.8% | 4,753.3% | |||
| Avg | - | -0.4% | 2,938.9% | |||
| Low | - | - | 1,209.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.19 | -0.60 | -0.63 | ||
| Avg | -2.21 | -0.64 | -0.63 | ||
| Low | -2.22 | -0.67 | -0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.